ROHDE-&-SCHWARZ
21.10.2020 15:02:11 CEST | Business Wire | Press release
In the past, the creation of software took about a year on average of development before being commercialized. Today, many organizations are adopting a continuous integration and deployment approach. Now, the cycle has become shorter, thanks in particular to DevOps, which relies on automation and the pooling of complementary skills to increase the added-value and responsiveness of companies.
The Rohde & Schwarz Cybersecurity strategy aims to help DevOps teams integrate application security right from the design phase, by integrating control capabilities within their APIs and applications. Rohde & Schwarz Cybersecurity has been offering Web Application Firewall (WAF) technologies for about twenty years. The company now makes its technologies consumable by developers. It offers tools that integrate into the environment and tools already existing and that use the same languages and technologies of the DevSecOps universe. It is in this context that Rohde & Schwarz Cybersecurity is launching R&S Trusted Application Factory.
Putting security at the heart of applications
R&S Trusted Application Factory is a solution for DevOps teams with the objective of providing security, simplicity and visibility.
- Security : By integrating security as close as possible to the application
- Simplicity : To simplify collaboration, the security solution must be integrated into the DevOps teams' universe. Thus, the same tools, languages and concepts must be used.
- Visibility : It is necessary to provide visibility to the various users and managers: developers, infrastructure and security. R&S Trusted Application Factory tracks the application from design to production execution, providing indicators on its security throughout its lifecycle.
The R&S Trusted Application Factory application security service is deployed as a container for each application. This container can therefore "evolve" at the same time as the application in Kubernetes or Docker clusters. It can therefore automatically adapt to the application load. It also accompanies the application and can be deployed on-demand as well as on the private or public cloud. All the services are managed from a SaaS administration console, which enables the security of the various applications to be monitored.
The solution is based on the concept of "Context Description" to improve the level of security. Indeed, the data specific to each application and available to the development teams are essential for the configuration of security. The type of persistence used, the programming language, the server operating system and the data formats make it possible to automatically adapt protection policies by invoking the appropriate engines. By taking all these elements into account, increased security and a reduced risk of false positives is achieved.
Rohde & Schwarz Cybersecurity
Rohde & Schwarz Cybersecurity is a leading IT security company that protects the digital assets of companies and public institutions worldwide from cyberattacks.
Rohde & Schwarz
Rohde & Schwarz is a leading supplier of solutions in the fields of test and measurement, broadcast and media, aerospace | defense | security and networks and cybersecurity.
R&S® is a registered trademark of Rohde & Schwarz GmbH & Co KG.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005500/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom